{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:48:52Z","timestamp":1794005332876,"version":"4.8.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"publisher","award":["2019YFC1316205"],"award-info":[{"award-number":["2019YFC1316205"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31991171, 31870873, 81830002"],"award-info":[{"award-number":["31991171, 31870873, 81830002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872479, 82022057"],"award-info":[{"award-number":["81872479, 82022057"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903153"],"award-info":[{"award-number":["81903153"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fostering Funds from the Chinese PLA General Hospital\u2019s National Excellent Young Scholar Science Fund","award":["2020-JQPY-001"],"award-info":[{"award-number":["2020-JQPY-001"]}],"id":[{"id":"https:\/\/ror.org\/04gw3ra78","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CD19-directed chimeric antigen receptor T cell (CART19) therapy is efficient and approved for relapsed\/refractory diffuse large B cell lymphoma (DLBCL). To increase durable antitumor response, we previously designed tandem CART19\/20 cells and shown longer progression-free survival. However, a proportion of CART19\/20-treated patients will finally progress and require salvage therapies. In this study, we analyzed data from five patients with relapsed\/refractory DLBCL who had disease progression or relapse following CART19\/20 therapy and then treated with PD-1-blocking antibodies as salvage therapy. Two of five patients acquired complete remissions after anti-PD-1 therapy, including one patient remained ongoing remission for more than 21\u00a0months. One patient achieved a partial remission, and the other two had progressive diseases. No\u2009\u2265\u2009grade 3 treatment-related adverse events or cytokine release syndrome was observed. Immunohistochemistry of tumor specimens revealed higher PD-1\/PD-L1 expression in responsive patients with anti-PD-1 therapy as compared to that in\u00a0non-responders. After anti-PD-1 treatment, circulating T cells were activated in responders, and no significant expansion of CART19\/20 cells was detected. Our data suggest that PD-1 blockade therapy can be active in patients with relapsed\/refractory DLBCL after failure of CAR T cell therapy who had PD-L1 expression in tumor cells and high PD-1 level in tumor-infiltrated T cells.<\/jats:p>","DOI":"10.1186\/s13045-021-01120-3","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T09:02:45Z","timestamp":1625475765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed\/relapsed after CART19\/20 therapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Chunmeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxia","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-3899","authenticated-orcid":false,"given":"Weidong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"1120_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ctrv.2018.01.002","volume":"65","author":"K Dunleavy","year":"2018","unstructured":"Dunleavy K, Erdmann T, Lenz G. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. Cancer Treat Rev. 2018;65:41\u20136.","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"1120_CR2","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12(11):1013\u201322.","journal-title":"Lancet Oncol"},{"issue":"18","key":"1120_CR3","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23(18):4117\u201326.","journal-title":"J Clin Oncol"},{"key":"1120_CR4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW. Relapsed\/refractory diffuse large B-cell lymphoma. Hematol Am Soc Hematol Educ Program. 2011;2011:498\u2013505.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"1","key":"1120_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1120_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jager U, Jaglowski S, Andreadis C, Westin JR, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"14","key":"1120_CR7","first-page":"1632","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, Han X, Ti D, Dai H, Wang C, et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood. 2020;136(14):1632\u201344.","journal-title":"Blood"},{"issue":"4","key":"1120_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"issue":"20","key":"1120_CR9","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","volume":"19","author":"LB John","year":"2013","unstructured":"John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636\u201346.","journal-title":"Clin Cancer Res"},{"key":"1120_CR10","doi-asserted-by":"publisher","first-page":"e49392","DOI":"10.7554\/eLife.49392","volume":"9","author":"D Kato","year":"2020","unstructured":"Kato D, Yaguchi T, Iwata T, Katoh Y, Morii K, Tsubota K, Takise Y, Tamiya M, Kamada H, Akiba H, et al. GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab. Elife. 2020;9:e49392.","journal-title":"Elife"},{"key":"1120_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3389\/fcell.2020.00803","volume":"8","author":"Y Ping","year":"2020","unstructured":"Ping Y, Li F, Nan S, Zhang D, Shi X, Shan J, Zhang Y. Augmenting the effectiveness of CAR-T cells by enhanced self-delivery of PD-1-neutralizing scFv. Front Cell Dev Biol. 2020;8:803.","journal-title":"Front Cell Dev Biol"},{"issue":"19","key":"1120_CR12","doi-asserted-by":"publisher","first-page":"4869","DOI":"10.1182\/bloodadvances.2020002292","volume":"4","author":"VA Chow","year":"2020","unstructured":"Chow VA, Gopal AK, Gauthier J, Tseng YD, Turtle CJ, Maloney DG, Shadman M. Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. Blood Adv. 2020;4(19):4869\u201372.","journal-title":"Blood Adv"},{"issue":"1","key":"1120_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13045-021-01044-y","volume":"14","author":"Y Liang","year":"2021","unstructured":"Liang Y, Liu H, Lu Z, Lei W, Zhang C, Li P, Liang A, Young KH, Qian W. CD19 CAR-T expressing PD-1\/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies. J Hematol Oncol. 2021;14(1):26.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1120_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/blood.2020006770","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM, Vakil A, et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood. 2021;137(3):323\u201335.","journal-title":"Blood"},{"issue":"8","key":"1120_CR15","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","volume":"129","author":"EA Chong","year":"2017","unstructured":"Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129(8):1039\u201341.","journal-title":"Blood"}],"updated-by":[{"DOI":"10.1186\/s13045-021-01154-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000}}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01120-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-021-01120-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-021-01120-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T04:42:33Z","timestamp":1632458553000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01120-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1186\/s13045-021-01120-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"27 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13045-021-01154-7","URL":"https:\/\/doi.org\/10.1186\/s13045-021-01154-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of Chinese PLA General Hospital, in accordance with the ethical principles of Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declared no potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}